

Clerk of the House of Representatives Legislative Resource Center B-106 Cannon Building Washington, DC 20515	Secretary of the Senate Office of Public Records 232 Hart Building Washington, DC 20510
---	--

SECRETARY OF THE SENATE  
 04 FEB 17 PM 12: 04

## LOBBYING REPORT

Lobbying Disclosure Act of 1995 (Section 5) - All Filers Are Required to Complete This Page

1. Registrant Name Winstead Sechrest & Minick, P.C.			
2. Address <input type="checkbox"/> Check if different than previously reported 1450 G Street NW, Suite 810, Washington, DC 20005			
3. Principal Place of Business (if different from line 2) Dallas Texas 75270 City: State/zip (or Country)			
4. Contact Name William LaForge	Telephone (202) 572-8000	E-mail (optional)	5. Senate ID # 42741-595
7. Client Name <input type="checkbox"/> Self Aventis Pharmaceuticals			6. House ID # 33542021



**TYPE OF REPORT** 8. Year 2003 Midyear (January 1-June 30)  OR Year End (July 1-December 31)

9. Check if this filing amends a previously filed version of this report

10. Check if this is a Termination Report  ⇨ Termination Date \_\_\_\_\_ 11. No Lobbying

### INCOME OR EXPENSES - Complete Either Line 12 OR Line 13

12. Lobbying Firms	13. Organizations
<b>INCOME</b> relating to lobbying activities for this reporting period was:  Less than \$10,000 <input checked="" type="checkbox"/>  \$10,000 or more <input type="checkbox"/> ⇨ \$ _____ Income (nearest \$20,000)	<b>EXPENSES</b> relating to lobbying activities for this reporting period were:  Less than \$10,000 <input type="checkbox"/>  \$10,000 or more <input type="checkbox"/> ⇨ \$ _____ Expenses (nearest \$20,000)
Provide a good faith estimate, rounded to the nearest \$20,000, of all lobbying related income from the client (including all payments to the registrant by any other entity for lobbying activities on behalf of the client).	<b>14. REPORTING METHOD.</b> Check box to indicate exp accounting method. See instructions for description of opt <input type="checkbox"/> <b>Method A.</b> Reporting amounts using LDA definition <input type="checkbox"/> <b>Method B.</b> Reporting amounts under section 6033(t) Internal Revenue Code <input type="checkbox"/> <b>Method C.</b> Reporting amounts under section 162(e) Internal Revenue Code

Signature William LaForge Date 4/17/01

Printed Name and Title William LaForge, Shareholder

LD-2 (REV. 4/03)

PAGE 1 of

Registrant Name Winstead Sechrest & Minick, P.C. Client Name Aventis Pharmaceuticals

**LOBBYING ACTIVITY.** Select as many codes as necessary to reflect the general issue areas in which the engaged in lobbying on behalf of the client during the reporting period. Using a separate page for each cod information as requested. Attach additional page(s) as needed.

15. General issue area code PHA (one per page)

16. Specific lobbying issues

Pharmaceutical issues.

17. House(s) of Congress and Federal agencies contacted  Check if None

U.S. House of Representatives  
Senate

18. Name of each individual who acted as a lobbyist in this issue area

Name	Covered Official Position (if applicable)
William LaForge	
Frederick McClure	

19. Interest of each foreign entity in the specific issues listed on line 16 above  Check if None

Signature  Date 2-12-04

Printed Name and Title William Laroge / Shareholder

Form LD-2 (Rev. 4/03)

Page 2